Irbesartan Tecnigen

Irbesartan, the active ingredient in Irbesartan Tecnigen, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It is used to treat chronic hypertension and to protect kidney function significantly in patients with type 2 diabetic nephropathy.

GNH USA supplies Irbesartan Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and transplant centres in over 50 countries with reliable logistics worldwide.

Irbesartan is an angiotensin II receptor blocker that manages conditions related to the renin‑angiotensin system.

- Hypertension: lowers elevated blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows progression of kidney disease in patients with type 2 diabetes. - Proteinuria: decreases urinary protein excretion, supporting renal protection.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate head discomfort. - Fatigue: general tiredness or lack of energy. - Nausea: feeling of stomach upset. - Elevated potassium: mild hyperkalaemia detectable in blood tests. - Upper respiratory infection: transient cold‑like symptoms.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure causing faintness. - Acute kidney injury: sudden decline in renal function. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Blood dyscrasias: rare blood cell abnormalities. - Pancreatitis: inflammation of the pancreas with abdominal pain.

Irbesartan should be used with careful monitoring and patient education.

- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Serum potassium checks: monitor for hyperkalaemia, especially with concomitant potassium‑sparing agents. - Hepatic impairment: use cautiously in patients with liver disease. - Pregnancy: contraindicated in pregnancy (Category D) due to fetal risk. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines that affect blood pressure, potassium balance, or renal function.

Major Interactions (Avoid): - Aliskiren (in diabetes): combined use can increase renal impairment and hyperkalaemia. - Dual ARB/ACE inhibitor therapy: heightened risk of hypotension and renal dysfunction. - Potassium‑sparing diuretics: may cause dangerous hyperkalaemia. - NSAIDs (high dose): can reduce renal perfusion and blunt antihypertensive effect. - Cyclosporine: increases risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect, requiring dose adjustment. - Lithium: can raise lithium levels, necessitating close monitoring. - Antidiabetic agents: may need dose modification due to improved glycaemic control. - Rifampin: may lower irbesartan plasma concentrations. - NSAIDs (low dose): monitor renal function and blood pressure.